Dr. Kuwayama teach a course in Seville
GINEMED GINEMED Foundation announces clinics and doctor's presence in the IV Kawayama Advanced Course and Vitrification Fertility Preservation, to be held on March 4 at the Hospital NISA Aljarafe Seville.
This is a theoretical and practical course, the first part is aimed at gynecologists, oncologists, biologists and other health professionals specialized in reproduction, interested in learning and deepen existing innovations in fertility preservation and medical applications in the field of Assisted Human Reproduction.
Meanwhile, the practical module of the course is aimed at professional biologists and related biohazardous, specialized in Human Reproduction, interested in setting up and optimizing egg vitrification technique for reproductive purposes.
Profile of Dr. Kuwayama
Dr. Masashige Kuwayama, initiated in 1986, a series of works in the field of bovine embryology, having developed various assisted reproductive techniques, which have been the basis of the current Assisted Human Reproduction (IVM, IVF, vitrification, growing embryo, ES cell).
Mechanism designed a series production of bovine embryos within a national project of Japan, developed in 1990. The result of this work, Professor Kuwayama the first calves obtained after vitrification of oocytes, in vitro fertilization, in vitro culture and blastocyst transfer in 1992.
All these advances in reproduction, are the basis of the current Assisted Human Reproduction, developed in 1999, the vitrification method for human oocytes Cryotop, establishing the first bank in 2001 human oocytes.
The first baby, after fertilization of vitrified eggs, born in 2000, in the U.S. and Japan, were obtained by using the method Cryotop.
In 2011, Dr. Kuwayama, has developed a new method, Cryotech, which allows 100% viability of oocytes after devitrification, which is a marked improvement over the method Cryotoc, also developed by Dr. Kuwayama.
Vitrification methods developed by Dr. Kuwayama are used in over 1,200 clinics around the world, in over 40 countries, and there are over 500,000 cases with successful results.